# US 2026/0125683 A1 · Treatment of cancers having a drug-resistant mesenchymal cell state

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125683 A1
- Document ID: US20260125683A1
- Status: Published application
- Kind: A1
- Application number: 19/327,780
- Filed: 2025-09-12
- Published: 2026-05-07
- Earliest claimed: 2023-03-13
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Andrew AGUIRRE; Kevin KAPNER; Kyle EVANS
- Web page: https://patentgrep.com/patent/US20260125683A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Y 207/07041: Phosphatidate cytidylyltransferase (2.7.7.41), i.e. CDP-diacylglycerol synthase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The subject matter disclosed herein is generally directed to methods of treating a tumor capable of an epithelial-to-mesenchymal transition (an EMT cancer) by targeting the mesenchymal cell state. Disclosed are novel gene dependencies in the mesenchymal cell state. Also, disclosed are novel drugs that target the mesenchymal cell state.

## Claims

### Claim at position 1

1-4. (canceled)

### Claim 5

A method for treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
administering to the subject one or more agents capable of inhibiting the expression or activity of CDS2, ELMO2, ITGAV, AP1M1, FERMT2, CHMP4B, PTK2, ITGB5, PRKAR1A, ACTR1A, SRF, ZEB1, MTOR, DNM1L PSMB7, MOB4, TEAD1, DOCK5, ACTR3, BCAR1, UFM1, TIPARP, ILK, RSU1, WWTR1, NCKAP1, ATP6V1C1, MYH9, FOSL1, LIMS1, GNB1, EFR3A, ARHGEF7, WDR7, PKN2, CEMIP2, TEAD1, CTDNEP1, MARK3, VCL, CDC42, BCAR1, EGLN1, UFM1, GPX4, and/or CRK,
thereby treating the subject having the EMT cancer.

### Claim at position 3

6-35. (canceled)

### Claim 36 (depends on 5)

The method of claim 5, comprising administering to the subject one or more agents capable of inhibiting CDS2 expression or activity.

### Claim 37 (depends on 5)

The method of claim 5, further comprising:
identifying the cancer as an EMT cancer by detecting in the cancer the expression of one or more genes identified as positively correlated with EMT Down signatures and/or as negatively correlated with EMT Up signatures,
wherein the one or more genes identified as positively correlated with EMT Down signatures are selected from among PTPN6, ILDR1, TSTD1, LCN2, MYO6, MFSD6, AMN, DDR1, PPL, C2orf15, AREG, CD9, FAM160A1, ENPP5, CD24, SMIM22, RAB25, PRRG2, CLDN4, RNF223, PLA2G4F, LLMO3, MAP7, MAL2, CBLC, KRTCAP3, MACC1, F11R, SPINT1, CNKSR1, CGN, IRF6, ESRP2, MPZL3, OVOL2, BSPRY, PRSS22, FXYD3, TJP2, PKP2, TMC5, RNF43, USP43, DLG3, PRKCZ, PKP3, ANO9, GRB7, JUP, CDH3, C11orf52, MYO5B, PATJ, TSPAN1, ZNF165, EPHA1, ELF3, BICDL22, TJP3, MUC20, MARVELD2, TC2N, CDS1, CLDN7, GRHL2, C1orf116, EPN3, PSD4, FAAH, OVOL1, SYNE4, IQANK1, MARVELD3, CRB3, KDF1, PRSS8, MAPK3, MAPK13, S100A14, ERBB3, GALNS, KRT19, EPS8L1, TMC4, ESRP1, SOWAHB, ST14, CDC42BPG, RAB17, CDH1, SH2D3A, LSR, B3GN3T, C1orf210, MPZL2, FUT3, SPINT2, C6orf132, PLEKHA7, TMC5, ICA1, TPD52L1, KLK8, SFTA2, KRT8, LAD1, IRF6, KLF5, PRR15, BICDL2, LIPH, LSR, FXYD3, EPCAM, MAL2, C2N, SPINT1, TCM5, ASS1, COBL, ACSL5, GPX2, MYZAP, KIAA1217, SCNN1A, B3GNT3, MISP, VGLL1, ITGB6, DOK7, HSH2D, SYT8, SH3YL1, SFN, TMEM125, TTC9, CST6, ACOT11, TUBA4A, PERP, ABHD11, BTC, CJB3, TNK1, LRRC1, ARRDC1, ANXA3, C11orf52, TCM4, ADIRF, LPAR5, GJB4, GJB5, MCTP2, TRIM31, HID1, DAPP1, SLPI, MST1R, LY75, CRYBG2, FUCA1, EPHA1, BIK, C1orf210, JUP, DDR1, LRG1, VAMP8, F3. CD9, TNK1, ILDR1, ITGB4, ESRP1, GALNT3, RNF223 MPZL2, EPCAM, B3GNT3, ST14, PTK7, GPR87, KCNK6, UPK2, HSH2D, KLF5, TMPRSS4, FRK, FAM83F, KRT19, TMC4, TC2N, PRRG2, RBM47, TC22, ITGB6, and TMEM125, and
wherein the one or more genes identified as negatively correlated with EMT Up signatures are selected from among PTCH2, TET3, AUNIP, E2F2, BEND3, CCSAP, INPP5J, RMND5B, PHF8, RAB11FIP4, OTUD3, KCNJ11, ZBTB39, STRBP, FZD3, SNK1, STRBP, PPFIA3, ADGRL1, FEM1A, MYCL, CHTOP, TICRR, CDS1, LHX4, PCNT, TCLD2, HDHD3, STRBP, CAMSAP3, C2orf15, DENND1C, IQANK1, MARVELD3, ZDHHC23, LNX2, ESRP2, BSPRY, LLGL2, SKY, CRB3, MAP7, MYH14, ERBB3, KDF1, OVOL1, HSD11B2, GLS2, MARVELD2, ARHGAP8, PRR5, CDS1, AP1Ar, EPB41, TET3, ESRP2, GAN, CDC42BPG, POU2F1, DDI2, ARHGAP8, STRBP, RREB1, LRRC8B, LLGL2, GRTP1, HOOK1, BSPRY, RDH13, SPATA2L, MCM9, PRR5, and RDH13.

### Claim 38 (depends on 5)

The method of claim 5, further comprising:
identifying the cancer as an EMT cancer by detecting in the cancer or in the subject the presence of one or more of the following metabolites: stearoylcarnitine, C16.0.SM, betaine, palmitoylcarnitine, adenosine, 6.phosphogluconate, 1.methylnicotinamide, anthranilic.acid, carnosine, and/or sorbitol.

### Claim 39

A method for identifying and treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
(a) detecting the expression in the cancer of one or more genes identified as positively correlated with CDS2 dependency selected from among PKP3, CDS1, MAL2, ELF3, IRF6, PATJ, CDH1, MAP7, ARHGEF16, ARHGEF5, TNK1, CNKSR1, ARHGAP8, CLDN4, IQANK1, CDH3, OVOL1, C11orf52, GRB7, GRHL2, C6orf132, MARVELD3, ESRP1, MPZL2, CHMP4C, TMEM125, TACSTD2, MYO5B, PRSS22, S100A14, SRP2, CRB3, EPCAM, RAB25, CLBC, TMEM184A, CLDN7, PRSS8, PRRG2, and SFN; and
(b) administering to the subject one or more agents capable of inhibiting CDS2 expression or activity,
thereby identifying and treating the subject having the EMT cancer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the one or more genes identified as positively correlated with CDS2 dependency is detected in the cancer below a reference value, wherein the reference value is determined by comparison to an appropriate control sample lacking the EMT cancer.

### Claim 41 (depends on 39)

The method of claim 39, wherein the one or more genes comprises CDS1.

### Claim 42

A method for identifying and treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
(a) detecting in the subject one or more metabolites identified as negatively correlated with CDS2 dependency, wherein the one or more metabolites is selected from among oxalate, C38.4.PC, AMP, C40.6.PC, C56.5.TAG, C50.0.TAG, trimethylamine.N.oxide, C58.7.TAG, C56.7.TAG, C36.4.PC.A, UMP, C22.1.SM, dCMP, C56.6.TAG, C58.6.TAG, C36.4.PC.B, C58.8.TAG, cytidine, CMP, C38.6.PC, alpha.glycophosphate, arachidonyl_carnitine, C38.5.PC, and C58.8.TAG; and
(b) administering to the subject one or more agents capable of inhibiting CDS2 expression or activity,
thereby identifying and treating the subject having the EMT cancer.

### Claim 43 (depends on 42)

The method of claim 42, wherein the one or more metabolites identified as negatively correlated with CDS2 dependency is detected in the subject above a reference value, wherein the reference value is determined by comparison to an appropriate control subject or sample lacking the EMT cancer.

### Claim 44 (depends on 5)

The method of claim 5, wherein the administering step is performed prior to, concurrently with, or after a primary cancer treatment.

### Claim 45 (depends on 5)

The method of claim 5, further comprising:
detecting cancer cells that express a mesenchymal signature after the administering step and comparing to the number of cancer cells expressing a mesenchymal signature before the administering step, wherein the treatment is identified as efficacious in the subject if the number of tumor cells expressing a mesenchymal signature decreases.

### Claim 46 (depends on 5)

The method of claim 5, wherein the one or more agents are one or more small molecules that reduce the activity or expression of CDS2 or the one or more genes.

### Claim 47 (depends on 46)

The method of claim 46, wherein the one or more small molecules is capable of binding to the active site of CDS2, wherein the active site is an antagonistic analog of 1-stearoyl-2-arachidonoyl-sn-phosphatidic acid, or an anionic phospholipid end product or analog thereof, or phosphatidylinositol-(4,5)-bisphosphate or derivatives thereof.

### Claim 48 (depends on 46)

The method of claim 46, wherein the one or more small molecules is a small molecule degrader capable of degrading CDS2 or the one or more genes.

### Claim 49 (depends on 5)

The method of claim 5, wherein the one or more agents is an RNAi or an antisense oligonucleotide (ASO).

### Claim 50 (depends on 5)

The method of claim 5, wherein the one or more agents is a transcriptional repressor system comprising a DNA binding element linked to or otherwise capable of complexing with a transcriptional repressor and configured to bind an enhancer of CDS2 or configured to bind the one or more genes.

### Claim 51 (depends on 5)

The method of claim 5, wherein the one or more agents is an epigenetic modification polypeptide comprising a DNA binding element linked to or otherwise capable of associating with an epigenetic modification domain such that binding of the DNA binding element at a target sequence on gDNA results in one or more epigenetic modifications by the epigenetic modification domain that decreases expression of CDS2 or the one or more genes.

### Claim 52 (depends on 51)

The method of claim 51, wherein the DNA binding element comprises a zinc finger protein or a DNA-binding domain thereof, a TALE protein or a DNA-binding domain thereof, or a Cas nuclease protein or a DNA-binding domain thereof.

### Claim 53 (depends on 5)

The method of claim 5, wherein the one or more agents is a gene editing system configured to modify CDS2 or the one or more genes, an enhancer associated with CDS2 or the one or more genes, or a mRNA encoding CDS2 or the one or more genes, such that expression or activity of CDS2 or the one or more genes is reduced.

### Claim 54 (depends on 53)

The method of claim 53, wherein the gene editing system is a zinc finger nuclease, a TALEN, a meganuclease, or a CRISPR-Cas system, a base editing system, CRISPR prime editing system, or a CRISPR-associated transposase (CAST) system.
